Zura Bio Reports Third Quarter 2026 GAAP EPS of -$0.20
Zura Bio has released its third-quarter financial results for 2026, reporting a GAAP earnings per share (EPS) of -$0.20. This figure was in line with market expectations as the company continues its operational activities. The company reported research and development (R&D) expenses totaling $19.5 million during the quarter. As of September 30, 2026, Zura Bio maintained a strong liquidity position with cash and cash equivalents amounting to $187.7 million.
Tickers: $ZURA